EUSA Pharma is a newly formed specialty pharmaceutical company headquartered in the UK which supplies medicines and medical devices across Europe through its own operations, and worldwide through a network of partners in over 40 countries.
Location: United Kingdom, England, Oxford
Total raised: $175M
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.03.2007 | - | $175M | - |
Mentions in press and media 13
| Date | Title | Description |
| 02.05.2025 | The New Wave of Acquisitions: Navigating Tariff Turbulence and Gaming Growth | In the ever-shifting landscape of global business, two companies stand out: Recordati and Dream Games. Both are poised for growth, but their paths diverge. Recordati, an Italian pharmaceutical firm, eyes acquisitions amid tariff volatility.... |
| 30.04.2025 | Italy’s Recordati Sees Tariff Volatility Fueling Dealmaking | (Bloomberg) -- Italian drugmaker Recordati SpA is on the lookout for acquisitions, saying market volatility and the impact of tariffs have created the potential for cheaper buyouts. Recordati, which is backed by private equity firm CVC Capi... |
| 02.04.2020 | UK tech companies tackling Covid-19 – from detection to vaccination | The 2020 Tech Nation Report revealed that UK healthtech investment has doubled since 2017, reaching £1.7bn in 2019. And this world-leading sector has just become more crucial than ever. Faced with a global pandemic, innovative scaling compa... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 19.03.2020 | FDA unveils guidance for Covid-19 trials | The FDA on Wednesday issued new final guidance to help sponsors assure the safety of trial participants, maintain compliance with good clinical practice (GCP) and minimize the risks to trial integrity during the Covid... |
| 18.07.2018 | EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ireland UC for $115 Million | Jul 18 2018 HEMEL HEMPSTEAD, England – – EUSA Pharma (EUSA), a biopharmaceutical company focused on oncology and rare diseases, announced today that it has entered into a definitive agreement with Janssen Sciences Ireland UC, a subsidiary ... |
| 18.07.2018 | EUSA PHARMA ANNOUNCES ACQUISITION OF GLOBAL RIGHTS TO SYLVANT® (SILTUXIMAB) FROM JANSSEN SCIENCES IRELAND UC FOR $115 MILLION | - |
| 18.11.2011 | Eusa Pharma gets green light for drug treatment of leukemia | Orphan drugs are classified as those treating niche patient populations of under 200,000. Eusa estimates that about 400-600 patients suffer allergic reactions from the treatment. Promoted This Patient Experience Checklist Is Your Key To Suc... |
| 11.03.2008 | Life-science briefing: Tuesday, March 11, 2008 | TODAY’S HEADLINES: Affinergy gets $3M in grants for biological “linkers” (release) Specialty pharma EUSA raises $50M, spends $23M for public biotech Cytogen (release) Calderome takes in $12M for cancer diagnostics (peHUB) Pulse Health raise... |
| 01.03.2007 | EUSA Pharma raises $175m for acquisitions and development led by 3i venture capital | EUSA Pharma Inc, a new transatlantic specialty pharmaceutical company focused on developing and marketing products for the hospital market both in Europe and theUnited States, announces the agreed acquisition of OPi SA (“OPi”), an integrate... |
Show more